Erick Lucera, CFA
Erick Lucera joined the SAB board of directors in April 2023, bringing thirty years of financial, operational, and investment experience in the biotechnology and medical device industry.
Currently, Mr. Lucera serves as Chief Financial Officer of Dyne Therapeutics. Prior to joining Dyne, he served as CFO of Editas Medicine, overseeing financial strategy, financing initiatives, strategic licensing transactions and infrastructure scaling to prepare the company for commercialization. Previously, as CFO of AVEO Pharmaceuticals, he led its transition from a clinical-stage company to commercialization, drove R&D pipeline growth and played a key role in its acquisition by LG Chem. Before that, he was CFO, treasurer, and secretary at Valeritas, where he helped develop the company’s global distribution strategy. Prior to Valeritas, Erick was CFO, Treasurer, and Secretary at Viventia Bio, where he prepared the company for an initial public offering. Erick also served as Vice President of Corporate Development at Aratana Therapeutics, securing multiple financings and managing licensing transactions and acquisitions to strengthen the company’s pipeline. Earlier in his career, he spent 15 years in investment management as a healthcare analyst.
Mr. Lucera holds a Certificate in Public Health from Harvard University, an MS in finance from Boston College, an MBA from Indiana University, and a BS in accounting from the University of Delaware.